Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data-Reference-Cited by-同舟云学术

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data

Published:2016-12-02 Issue:4 Volume:20 Page:328-336
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Li Nanxin¹,Yang Xi¹,Fan Liangyi¹,Totev Todor¹,Guerin Annie²,Chen Lei³,Bhattacharyya Subrata⁴,Joseph George³

Affiliation:

1. Analysis Group, Boston, MA, USA;

2. Analysis Group, Montreal, QC, Canada;

3. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

4. Novartis Healthcare Pvt. Ltd., Hyderabad, India

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1261032

Reference50 articles.

1. NIH National Cancer Institute. Surveillance, epidemiology, and end results program (SEER) stat fact sheets: Chronic Myeloid Leukemia (CML). 2015, http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed October 27, 2015

2. National Academy of Sciences: Abstracts of Papers Presented at the Autumn Meeting, 14-16 November 1960, Philadelphia, Pennsylvania

3. Deletion of the 5′ abl region in Philadelphia chromosome-positive chronic myeloid leukemia

4. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]

5. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

2. A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia;PharmacoEconomics;2022-09-30

3. Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis;Frontiers in Pharmacology;2021-10-19

4. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy;PharmacoEconomics - Open;2021-07-23

5. Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia;Therapeutics and Clinical Risk Management;2021-06